Skip to main content

Alexandria Real Estate Equities (ARE) Stock Analysis

SellVALUE-TRAP 1/5Moderate Confidence

Real Estate · REIT - Office

Sell if holding. Momentum 1.3/10 is below the 5.0 floor at $40.99 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Consecutive earnings misses (3); Concentration risk — Property Type: life science.

Alexandria Real Estate Equities is a life science REIT owning, operating, and developing Megacampus ecosystems in AAA life science clusters including Greater Boston, San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and NYC. It had 35.9M RSF of operating... Read more

$40.99+19.1% A.UpsideScore 4.1/10#13 of 14 REIT - Office
Stop $38.23Target $48.91(analyst − 13%)A.R:R 1.8:1
Analyst target$56.21+37.1%14 analysts
$48.91our TP
$40.99price
$56.21mean
$70

Sell if holding. Momentum 1.3/10 is below the 5.0 floor at $40.99 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Consecutive earnings misses (3); Concentration risk — Property Type: life science. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.1/10, moderate confidence.

Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 81d clear, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.

Thesis

Rewards
Attractive valuation
Risks
Concentration risk — Property Type: life science
Consecutive earnings misses (3)
Negative news sentiment (-0.93)

Key Metrics

P/E (TTM)
P/E (Fwd)-513.1
Mkt Cap$7.2B
EV/EBITDA12.5
Profit Mgn-36.1%
ROE-4.1%
Rev Growth-11.5%
Beta1.34
Dividend9.94%
Rating analysts22

Quality Signals

Piotroski F6/9

Options Flow

P/C1.73bearish
IV58%elevated

Concentration Risks(10-K Item 1A)

  • HIGHPropertylife science
    10-K Item 1A: 'We are dependent on the health of the life science industry, and changes within this industry...may adversely impact their ability to make rental payments to us'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Revenue shrinking — -11.5% YoY. Growth thesis broken unless recovery story develops.static

Revenue Growth
0.0
Declining revenue: -12%
Low model confidence on this dimension (33%).

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Volume
0.0
Obv
1.0
Ma Position
1.0
Rsi
4.5
Volume distribution (falling OBV)Below 200-MA, MA slope -5.7%/30d — confirmed downtrend

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
0.0
Quality Rank
0.7
Value Rank
6.4
GatesMomentum 1.3<4.5Death cross (50MA < 200MA)A.R:R 1.8 ≥ 1.5Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY 81d clearSEMI CYCLE PEAK CLEARSuitability: Aggressive
RSI
46 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $39.41Resistance $49.18

Price Targets

$38
$49
A.Upside+19.3%
A.R:R1.8:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Momentum score 1.3/10 — below 4.5 minimum
! Death cross — 50-day MA below 200-day MA

Earnings

B
M
M
M
1/4 beats
Next Earnings2026-07-20 (81d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is ARE stock a buy right now?

Sell if holding. Momentum 1.3/10 is below the 5.0 floor at $40.99 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Consecutive earnings misses (3); Concentration risk — Property Type: life science. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $38.23. Score 4.1/10, moderate confidence.

What is the ARE stock price target?

Take-profit target: $48.91 (+19.1% upside). Prior stop was $38.23. Stop-loss: $38.23.

What are the risks of investing in ARE?

Concentration risk — Property Type: life science; Consecutive earnings misses (3); Negative news sentiment (-0.93).

Is ARE overvalued or undervalued?

Alexandria Real Estate Equities trades at a P/E of N/A (forward -513.1). TrendMatrix value score: 7.5/10. Verdict: Sell.

What do analysts say about ARE?

22 analysts cover ARE with a consensus score of 3.4/5. Average price target: $56.

What does Alexandria Real Estate Equities do?Alexandria Real Estate Equities is a life science REIT owning, operating, and developing Megacampus ecosystems in AAA...

Alexandria Real Estate Equities is a life science REIT owning, operating, and developing Megacampus ecosystems in AAA life science clusters including Greater Boston, San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and NYC. It had 35.9M RSF of operating properties and 90.9% occupancy as of December 31, 2025. Investment-grade or publicly traded large-cap tenants represented 53% of annual rental revenue.

Related stocks: FISK (Empire State Realty OP, L.P. Se) · OGCP (Empire State Realty OP, L.P. Se) · ESBA (Empire State Realty OP, L.P. Se) · BXP (BXP, Inc.) · CUZ (Cousins Properties Incorporated)